Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs
Bloomberg BNA
Aug
5
2015
Date: August 5, 2015
Time: 9:00AM - 10:00AM
Topics
- Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs
Mintz Levin attorneys Ellyn Sternfield, Theresa Carnegie, and Joanne Hawana will be presenting a Bloomberg BNA Webinar entitled, "Will State Action on Biosimilars Thwart Anticipated Savings for Health Care Programs?" on August 5th. They discuss the state action on biosimilars, potential cost savings for Health Care Programs, the role of the FDA, and the CMS guidance addressing Medicare and Medicaid coverage and reimbursement of FDA-approved biosimilar drug products.
Educational Objectives:
- Discuss the state action on biosimilars
- Explore potential cost savings for health care programs
- Address the role of the Federal Drug Administration’s approval of biosimilar drug products
- Review the Centers for Medicare and Medicaid services guidance addressing Medicare and Medicaid coverage and reimbursement of FDA-approved biosimilar drug products
Speakers
Theresa C. Carnegie
Panelist
Theresa advises clients on all aspects of the pharmaceutical supply chain, including counseling industry stakeholders on a range of business, legal, transactional, and compliance matters. She provides clients with strategic counseling and creative business modeling that considers legal restrictions and regulatory risk in light of innovation and business goals.
Panelist
Joanne S. Hawana
Panelist
Joanne counsels global clients on the regulatory and distribution-related implications when bringing a new FDA-regulated product to market and how to ensure continued compliance after a product is commercialized.